Lorukafusp alfa

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** A recombinant fusion protein comprised of hu14.18, a humanized immunoglobulin G1 (IgG1) chimeric monoclonal antibody directed against the surface disialoganglioside GD2, fused to two human pro-inflammatory cytokine interleukin (IL)-2 molecules, with potential antineoplastic and immunomodulatory activities. Upon intravenous administration, the antibody moiety of lorukafusp alfa specifically targets and binds to GD2 expressed on certain tumor cells. This may stimulate the activation of immune effector cells including natural killer (NK) and T-cells, leading to tumor cell death via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and GD2-specifc T-cell responses. By delivering IL-2 directly to the tumor microenvironment (TME), IL-2 is able to further stimulate NK and T-cell antitumor cellular immune responses locally. The glycosphingolipid GD2 is a tumor-associated antigen (TAA) overexpressed on the surface of many tumor cells.

**Synonyms:** - APN 301 - APN-301 - APN301 - EMD 273063 - EMD-273063 - Hu 14.18/IL - 2 Fusion Protein - Hu14.18-IL2 - Hu14.18-IL2 - Hu14.18-IL2 Fusion Protein EMD 273063 - LORUKAFUSP ALFA - hu14.18-interleukin-2 fusion protein